Patents by Inventor Ashvinikumar V. Gavai

Ashvinikumar V. Gavai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7846931
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: December 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION
    Publication number: 20100256180
    Abstract: Disclosed are fused heterocyclic compounds of Formula (I): or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 31, 2008
    Publication date: October 7, 2010
    Applicant: BRISTOL-MYERS SQUIBB COMAPANY
    Inventors: Weifang Shan, James Aaron Balog, Ashvinikumar V. Gavai, Yufen Zhao
  • PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND METHODS OF TREATING KINASE-ASSOCIATED CONDITIONS THEREWITH
    Publication number: 20100137319
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Application
    Filed: February 5, 2010
    Publication date: June 3, 2010
    Inventors: Harold Mastalerz, Dolatral M. Vyas, George L. Trainor, Ashvinikumar V. Gavai
  • IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
    Publication number: 20100113458
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: October 8, 2009
    Publication date: May 6, 2010
    Inventors: Brian E. Fink, Libing Chen, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Andrew James Nation, Yufen Zhao, Litai H. Zhang
  • PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND METHODS OF TREATING KINASE-ASSOCIATED CONDITIONS THEREWITH
    Publication number: 20090062288
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Application
    Filed: October 28, 2008
    Publication date: March 5, 2009
    Inventors: Harold Mastalerz, Dolatrai M. Vyas, George L. Trainor, Ashvinikumar V. Gavai
  • PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20090048244
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Application
    Filed: September 24, 2008
    Publication date: February 19, 2009
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Alkylene bridged sultam compounds useful as modulators of nuclear hormone receptor function
    Patent number: 7468439
    Abstract: Disclosed are sultam compounds of Formula (I) or a pharmaceutically-acceptable salt thereof. Also disclosed are methods of using such compounds in the treatment of at least one nuclear hormone receptor-associated condition, such as, for example, cancer and immune disorders, and at least one pharmaceutical composition comprising such compounds.
    Type: Grant
    Filed: September 5, 2007
    Date of Patent: December 23, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Weifang Shan, James Aaron Balog, Andrew James Nation, Ashvinikumar V. Gavai, Wen-Ching Han, Mark E. Salvati
  • Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
    Patent number: 7442700
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: October 28, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Harold Mastalerz, Dolatrai M. Vyas, George L. Trainor, Ashvinikumar V. Gavai
  • Fused tricyclic compounds as inhibitors of 17?-hydroxysteroid dehydrogenase 3
    Patent number: 7417040
    Abstract: Disclosed are fused tricyclic compounds of the following formula I, or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof. The disclosed compounds are useful as inhibitors of 17?-hydroxysteriod dehydrogenase 3 (17?HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: August 26, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Wen-Ching Han, Raj N. Misra, Hai-Yun Xiao, Derek J. Norris, John S. Tokarski
  • Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
    Patent number: 7405213
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: July 29, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ping Chen, Derek J. Norris, Ashvinikumar V. Gavai
  • Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
    Patent number: 7402582
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: July 22, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Ping Chen, Derek J. Norris
  • Fused heterotricyclic compounds as inhibitors of 17?-hydroxysteroid dehydrogenase 3
    Patent number: 7378426
    Abstract: Disclosed are fused heterotricyclic compounds of the following formula I, or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of A ring or C ring is a 5-7 membered unsaturated heterocyclic ring. The disclosed compounds are useful as inhibitors of 17?-hydroxysteroid dehydrogenase 3 (17?-HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: May 27, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Derek J. Norris, Wen-Ching Han, Gregory D. Vite, Brian E. Fink, John S. Tokarski
  • ATP competitive kinase inhibitors
    Patent number: 7358256
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: April 15, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Ping Chen, Yufen Zhao
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7297695
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: November 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • Pyrrolotriazine compounds
    Patent number: 7151176
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: December 19, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Wen-Ching Han, Yufen Zhao, Ping Chen
  • C-6 modified indazolylpyrrolotriazines
    Patent number: 7148220
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: December 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Ashvinikumar V. Gavai, Brian E. Fink, Harold Mastalerz, John F. Kadow
  • Pyrrolotriazine compounds as kinase inhibitors
    Patent number: 7141571
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Ashvinikumar V. Gavai, Gregory D. Vite, Ping Chen, Harold Mastalerz, Derek J. Norris, John S. Tokarski, Yufen Zhao, Wen-Ching Han
  • 2-substituted cyclic amines as calcium sensing receptor modulators
    Patent number: 7105537
    Abstract: The present invention relates to modulators of the calcium sensing receptor having the formula I wherein Ar1, X, n, R1, R2, R3 and Q are as defined herein.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: September 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Roy J. Vaz, John K. Dickson, Jr., Jacques Y. Roberge, Wu Yang, Timur Gungor, James R. Corte, David P. Rotella, Yufeng Wang
  • Process for preparing pyrrolotriazine
    Patent number: 7102001
    Abstract: The present invention provides a process for preparing compounds of formula (I) or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shankar Swaminathan, Ashvinikumar V. Gavai, Junying Fan, Bharat P. Patel, Derek J. Norris, Richard Michael Corbett, Bin Zheng
  • Pyrrolotriazine compounds
    Patent number: 7102003
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Harold Mastalerz, Jean-Paul Daris, Pierre Dextraze, Philippe Lapointe, Edward H. Ruediger, Dolatrai M. Vyas, Guifen Zhang